Why Now Is the Defining Moment for Targeted Radiopharmaceuticals
Targeted radiopharmaceuticals have reached a critical inflection point.
Once viewed as a niche modality, radioligand therapies (RLTs) are now rapidly moving toward the center of precision oncology. Major pharma acquisitions, accelerating pipelines, and unprecedented infrastructure investment are reshaping what is possible - not just scientifically, but commercially and clinically.
The question facing the industry today is no longer if targeted radiopharmaceuticals will transform cancer care, but how fast teams can overcome the barriers standing between early promise and scalable clinical impact.
How the 2026 Agenda Responds to Today’s Industry Drivers
Discovery: New Targets, Smarter Design
As RLT programs expand beyond first‑generation targets, discovery teams need rigorously validated strategies to improve clinical translation. This track delivers practical approaches to target validation, ligand optimization, and radionuclide selection for stronger, more differentiated candidates.
Preclinical: Advancing with Confidence
Translational & Clinical: Breaking the Phase 0/1 Bottleneck
Clinical pipelines are surging - but bottlenecks remain. This track supports teams navigating early clinical trials, benchmarking dosimetry strategies, optimizing trial design, and ensuring manufacturing readiness as programs move toward scale.
CMC & Supply Chain: Building for Scale
Isotope innovation is unlocking new opportunities - and new dependencies. Sessions dive into emerging isotopes such as Astatine and Terbium, evolving supply infrastructure, clinical site readiness, and CMC strategies required for late‑stage trials and commercialization.
What to Expect in 2026
A More Focused, More Actionable Agenda
Built directly from 2025 attendee feedback and market research, the 2026 program prioritizes practical decision‑making over theory, with sessions designed to help teams solve real development, clinical, and supply challenges. Expect sharper case studies, clearer benchmarks, and lessons you can apply immediately within your own RLT programs.
More Industry Voices, More Fresh Perspectives
Guidance Driven by Scientific Leadership
A dedicated Scientific Advisory Board plays a central role in shaping the program, ensuring technical rigor, relevance, and depth across all tracks. This guarantees content that resonates with the realities teams face at the bench, the clinic, and the manufacturing floor.
Structured Opportunities to Build the Right Partnerships
The summit’s 1‑to‑1 partnering program returns in 2026, giving attendees dedicated time to meet potential collaborators, solution providers, and strategic partners - supporting faster progress and smarter outsourcing decisions in an increasingly complex development environment.
Why This Launch Matters
As the industry transitions from proof‑of‑concept to scalable precision oncology, the decisions made today around targets, isotopes, trials, and infrastructure will define which programs succeed.
That’s why now is the moment to connect, benchmark, and move forward with clarity.
Explore the Full Event Guide
- 260+ Attendees from World-Leading RLT Companies
- 66+ Speakers including Novartis, AstraZeneca, RayzeBio & Convergent Therapeutics
- 8+ Hours of Dedicated Networking alongside pioneers in the RLT industry
- 4 Tracks of Content: An agenda built for your team, spanning from Discovery to
CMC & Supply Chain - 22+ C-Suite Speakers with direct influence on their companies’ pipelines & decision-making
